Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis
Published version of a preprint
Abstract
Purpose: Reactivation of p53 tumor suppressor activity in diseases such as soft-tissue sarcoma is considered an attractive means of targeted therapy. By systematically assessing alterations affecting the p53 pathway, we aimed to (a) classify sarcoma subtypes, (b) define a potential role in malignancy, and (c) identify potential patient biomarkers in this heterogeneous disease. Experimental Design: We have mapped mutational events in a panel of 192 benign or malignant bone and soft-tissue sarcomas. Analyses included TP53 and CDKN2A mutational and SNP status, MDM2 and MDM4 amplification and MDM2 SNP309 status. Results: We found an inverse relationship between MDM2 amplification and TP53 mutations, with a predominantly wild-type CDKN2A background. A high rate of point mutations in TP53 was observed uniquely in leiomyosarcoma, osteosarcoma, and MFH. Both MDM2 and MDM4 were also amplified in a subtype-specific manner, which was frequently seen as a coamplification event. We have also analyzed the risk allele frequencies for MDM2 SNP309, and show that the G allele was strongly associated with both liposarcomas and MDM2 amplification. Conclusions: Our data emphasize the critical role of p53 inactivation in sarcomagenesis, whereby different pathway alterations may be related to the heterogeneity of the disease. Moreover, we observed a strong association of malignancy with TP53 mutation, or MDM2 amplification and the presence of a G allele in SNP309, especially in lipoma versus liposarcoma. We propose, therefore, that MDM2 markers along with TP53 sequencing should be considered as patient biomarkers in clinical trials of sarcomas using MDM2 antagonists. Clin Cancer Res; 17(3); 416–26. ©2010 AACR.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Amplification of MDM genes or altered expression of MDM proteins is a feature of many tumours.
“Amplification of MDM genes or altered expression of MDM proteins is a feature of many tumours3–10 (Table 1).”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [8]
MDM2 and MDMX are deregulated in many human cancers and act oncogenically mainly by inhibiting p53.
“The MDM2 and MDMX (also known as HDMX and MDM4) proteins are deregulated in many human cancers and exert their oncogenic activity predominantly by inhibiting the p53 tumour suppressor.”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [8]
Cites
Baltosser, W. H., & Zar, J. H. (1996) · Ecology · doi:10.2307/2265725 · Cited by 35,166 · see citing works
Zar, J. H. (1996) · Cited by 7,905 · see citing works
Biostatistical Analysis (2nd ed.).
Breen, T. J., & Zar, J. H. (1986) · Journal of the American Statistical Association · doi:10.2307/2289268 · Cited by 5,815 · see citing works
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · see citing works
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017 · see citing works
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1× · see citing works
“A central regulator of p53 is the proto-oncogene Mdm2, which functions as an E3 ubiquitin ligase promoting p53 degradation (3, 4).”
BackgroundPetitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 4× · see citing works
“Somatic p53 mutations have been reported in 20% to 33% of all sarcomas (2, 18).”
BackgroundInfluentialTumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566 · see citing works
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas
Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286 · see citing works
Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265 · see citing works
Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., & Sherr, C. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8292 · Cited by 899 · see citing works
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881 · see citing works
p53 polymorphisms: cancer implications
Whibley, C., Pharoah, P. D. P., & Hollstein, M. C. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2584 · Cited by 667 · see citing works
MDMX: a novel p53‐binding protein with some functional properties of MDM2.
Shvarts, A., Steegenga, W. T., Riteco, N., van Laar, T., Dekker, P., Bazuine, M., van Ham, R. C., van der Houven van Oordt, W., Hateboer, G., van der Eb, A. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00919.x · Cited by 648 · see citing works
Inactivation of the p53 pathway in retinoblastoma
Laurie, N. A., Donovan, S. L., Shih, C.-S., Zhang, J., Mills, N., Fuller, C., Teunisse, A., Lam, S., Ramos, Y., Mohan, A., et al. (2006) · Nature · doi:10.1038/nature05194 · Cited by 595 · see citing works
p53 Mutation and MDM2 amplification in human soft tissue sarcomas.
Leach, F. S., Tokino, T., Meltzer, P. S., Burrell, M., Oliner, J., Smith, S., HILL, D. E., Sidransky, D., Kinzler, K. W., & Vogelstein, B. (1993) · PubMed · Cited by 533 · see citing works
BRAFMutation in Metastatic Colorectal Cancer
Tol, J., Nagtegaal, I. D., & Punt, C. J. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0904160 · Cited by 524 · see citing works
The pathological response to DNA damage does not contribute to p53-mediated tumour suppression
Christophorou, M. A., Ringshausen, I., Finch, A. J., Swigart, L. B., & Evan, G. I. (2006) · Nature · doi:10.1038/nature05077 · Cited by 382 · see citing works
Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4
Marine, J.-C., Francoz, S., Maetens, M., Wahl, G., Toledo, F., & Lozano, G. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401912 · Cited by 352 · see citing works
Mutation spectrum of the p53 gene in bone and soft tissue sarcomas.
Toguchida, J., Yamaguchi, T., Ritchie, B., Beauchamp, R. L., Dayton, S. H., Herrera, G. E., Yamamuro, T., Kotoura, Y., Sasaki, M. S., & Little, J. B. (1992) · PubMed · Cited by 297 · see citing works
Molecular Pathogenesis of Osteosarcoma
Kansara, M., & Thomas, D. M. (2007) · DNA and Cell Biology · doi:10.1089/dna.2006.0505 · Cited by 273 · see citing works
Self-citationWell-differentiated and dedifferentiated liposarcomas
Coindre, J., Pédeutour, F., & Aurias, A. (2009) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-009-0815-x · Cited by 254 · see citing works
Singer, S., Socci, N. D., Ambrosini, G., Sambol, E. B., DeCarolis, P. L., Wu, Y. V., O’Connor, R., Maki, R. G., Viale, A. J., Sander, C., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0584 · Cited by 249 · see citing works
The differential impact of p16INK4a or p19ARF deficiency on cell growth and tumorigenesis
Sharpless, N. E., Ramsey, M. R., Balasubramanian, P., Castrillon, D. H., & DePinho, R. A. (2004) · Oncogene · doi:10.1038/sj.onc.1207074 · Cited by 224 · cited 1× · see citing works
“Germline inactivation of ARF results in tumor development in mice, and bypasses the need for inactivation of p53 to immortalize fibroblasts (10, 11).”
BackgroundWang, T., Maierhofer, C., Speicher, M. R., Christoph Lengauer, C., Vogelstein, B., Kinzler, K. W., & Velculescu, V. E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202610899 · Cited by 223 · see citing works
Chelala, C., Khan, A., & Lemoine, N. R. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn653 · Cited by 219 · see citing works
Tsuchiya, T., Sekine, K., Hinohara, S.-I., Namiki, T., Nobori, T., & Kaneko, Y. (2000) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(99)00255-1 · Cited by 177 · see citing works
Italiano, A., Bianchini, L., Gjernes, E., Keslair, F., Ranchère‐Vince, D., Dumollard, J., Haudebourg, J., Leroux, A., Mainguene, C., Terrier, P., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3185 · Cited by 141 · see citing works
Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice
Lin, P. P., Pandey, M. K., Jin, F., Raymond, A. K., Akiyama, H., & Lozano, G. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp180 · Cited by 122 · see citing works
Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A
Müller, C. R., Paulsen, E. B., Noordhuis, P., Pedeutour, F., Sæter, G., & Myklebost, O. (2007) · International Journal of Cancer · doi:10.1002/ijc.22643 · Cited by 119 · see citing works
Costa, S., Pinto, D., Pereira, D., Rodrigues, H., Cameselle‐Teijeiro, J., Medeiros, R., & Schmitt, F. C. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-32 · Cited by 114 · see citing works
Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome
Palmero, E. I., Achatz, M. I., Ashton‐Prolla, P., Olivier, M., & Hainaut, P. L. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328333bf00 · Cited by 105 · see citing works
Mælandsmo, G. M., Berner, J. M., Flørenes, V. A., Forus, A., Hovig, E. J., Fodstad, Ø., & Myklebost, O. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.344 · Cited by 102 · see citing works
Rubio, R., Garcı́a-Castro, J., Gutiérrez-Aranda, I., Paramio, J. M., Santos, M., Catalina, P., Leone, P., Menéndez, P. R., & Rodrı́guez, R. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4640 · Cited by 101 · see citing works
Saddler, C. M., Ouillette, P. D., Kujawski, L. A., Shangary, S. K., Talpaz, M., Kaminski, M. S., Erba, H. P., Shedden, K., Wang, S., & Malek, S. N. (2007) · Blood · doi:10.1182/blood-2007-09-112698 · Cited by 96 · see citing works
MDM2 and MDMX can interact differently with ARF and members of the p53 family
Wang, X., Arooz, T., Siu, W. Y., Chiu, C. H. S., Lau, A., Yamashita, K., & Poon, R. Y. C. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02124-x · Cited by 94 · see citing works
Bartel, F., Schulz, J., Böhnke, A., Blümke, K., Kappler, M., Bache, M., Schmidt, H., Würl, P., Taubert, H. W., & Hauptmann, S. (2005) · International Journal of Cancer · doi:10.1002/ijc.21206 · Cited by 93 · see citing works
Mdm2 and Mdm4 Loss Regulates Distinct p53 Activities
Barboza, J., Iwakuma, T., Terzian, T., El‐Naggar, A. K., & Lozano, G. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2079 · Cited by 89 · see citing works
Oda, Y., Yamamoto, H., Takahira, T., Kobayashi, C., Kawaguchi, K., Tateishi, N., Nozuka, Y., Tamiya, S., Tanaka, K., Matsuda, S., et al. (2005) · The Journal of Pathology · doi:10.1002/path.1848 · Cited by 76 · see citing works
MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation
Jackson, M. W., Lindström, M. S., & Berberich, S. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010685200 · Cited by 74 · see citing works
Alterations of INK4A and INK4B Genes in Adult Soft Tissue Sarcomas: Effect on Survival
Orlow, I., Drobnjak, M., Zhang, Z., Lewis, J., Woodruff, J. M., Brennan, M. F., & Cordon‐Cardo, C. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.1.73 · Cited by 69 · see citing works
No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer
Campbell, I., Eccles, D., & Choong, D. Y. H. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.09.003 · Cited by 69 · see citing works
Walter, H., Radig, K., Ryś, J., Bosse, A., Kuhnen, C., Hoang‐Vu, C., Roessner, A., & Schneider‐Stock, R. (1998) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s004320050211 · Cited by 67 · see citing works
DNA hypermethylation status of multiple genes in soft tissue sarcomas
Kawaguchi, K., Oda, Y., Saito, T., Yamamoto, H., Takahira, T., Kobayashi, C., Tamiya, S., Tateishi, N., Iwamoto, Y., & Tsuneyoshi, M. (2005) · Modern Pathology · doi:10.1038/modpathol.3800502 · Cited by 66 · see citing works
Toffoli, G., Biason, P., Russo, A. G., Mattia, E. D., Cecchin, E., Hattinger, C. M., Pasello, M., Alberghini, M., Ferrari, C., Scotlandi, K., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2249 · Cited by 62 · see citing works
Aberrant Methylation of p14ARF Gene Correlates with Poor Survival in Osteosarcoma
Oh, J. H., Kim, H.-S., Kim, H., Kim, W. H., & Lee, S. H. (2006) · Clinical Orthopaedics and Related Research · doi:10.1097/01.blo.0000188063.56091.69 · Cited by 52 · see citing works
Involvement ofINK4A gene products in the pathogenesis and development of human osteosarcoma
Benassi, M. S., Molendini, L., Gamberi, G., Magagnoli, G., Ragazzini, P., Gobbi, G., Sangiorgi, L., Pazzaglia, L., Asp, J., Brantsing, C., et al. (2001) · Cancer · doi:10.1002/1097-0142(20011215)92:12 · Cited by 47 · see citing works
Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer
Ashton, K. A., Proietto, A. M., Otton, G. R., Symonds, I., McEvoy, M., Attia, J., Gilbert, M. B., Hamann, U., & Scott, R. J. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.12.036 · Cited by 45 · see citing works
Talseth‐Palmer, B. A., Meldrum, C. J., Suchy, J., Kurzawski, G., Lubiński, J., & Scott, R. J. (2006) · International Journal of Cancer · doi:10.1002/ijc.22339 · Cited by 44 · see citing works
High prevalence of p53 exon 4 mutations in soft tissue sarcoma
Das, P. K., Kotilingam, D., Korchin, B., Liu, J., Yu, D., Lazar, A. J., Pollock, R. E., & Lev, D. C. (2007) · Cancer · doi:10.1002/cncr.22680 · Cited by 37 · see citing works
Tumor suppression by ARF: Gatekeeper and caretaker
Dominguez‐Brauer, C., Brauer, P. M., Chen, Y., Pimkina, J. S., & Raychaudhuri, P. (2010) · Cell Cycle · doi:10.4161/cc.9.1.10350 · Cited by 37 · see citing works
Torquato, S. (2002) · Interdisciplinary applied mathematics · doi:10.1007/978-1-4757-6355-3_1 · Cited by 31 · see citing works
Zaykin, D. V., & Young, S. S. (2005) · Pharmacogenomics · doi:10.1517/14622416.6.1.77 · Cited by 18 · see citing works
Self-citationYoung, S. S., & Ge, N. (2005) · Pharmacogenomics · doi:10.1517/14622416.6.1.65 · Cited by 15 · see citing works
Self-citation
Flagged first, then by citations
2 of the 57 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279 · see citing works
Advances in sarcoma genomics and new therapeutic targets
Taylor, B. S., Barretina, J. G., Maki, R. G., Antonescu, C. R., Singer, S., & Ladanyi, M. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3087 · Cited by 428 · see citing works
FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
Guagnano, V., Kauffmann, A., Wöhrle, S., Stamm, C., Ito, M., Barys, L., Pornon, A., Yao, Y., Li, F., Zhang, Y., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0210 · Cited by 344 · see citing works
Self-citationIntegrative genomic and transcriptomic analysis of leiomyosarcoma
Chudasama, P., Mughal, S. S., Sanders, M. A., Hübschmann, D., Chung, I., Deeg, K. I., Wong, S.-H., Rabe, S., Hlevnjak, M., Zapatka, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02602-0 · Cited by 303 · see citing works
Lechner, M., Frampton, G. M., Fenton, T. R., Feber, A., Palmer, G. A., Jay, A., Pillay, N., Forster, M. D., Cronin, M. T., Lipson, D., et al. (2013) · Genome Medicine · doi:10.1186/gm453 · Cited by 219 · see citing works
Epidemiology and Etiology of Sarcomas
Hui, J. Y. C. (2016) · Surgical Clinics of North America · doi:10.1016/j.suc.2016.05.005 · Cited by 217 · see citing works
Synovial Sarcoma: Recent Discoveries as a Roadmap to New Avenues for Therapy
Nielsen, T. O., Poulin, N., & Ladanyi, M. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1246 · Cited by 172 · see citing works
Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
Nag, S. A., Zhang, X., Srivenugopal, K. S., Wang, M.-H., Wang, W., & Zhang, R. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113206660325 · Cited by 151 · see citing works
TP53 in bone and soft tissue sarcomas
Thoenen, E. A., Curl, A., & Iwakuma, T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.06.010 · Cited by 137 · see citing works
Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas
Italiano, A., Chen, C., Thomas, R. J., Breen, M., Bonnet, F., Sévenet, N., Longy, M., Maki, R. G., Coindre, J., & Antonescu, C. R. (2012) · Cancer · doi:10.1002/cncr.27614 · Cited by 122 · see citing works
Targeted genomic analysis of Müllerian adenosarcoma
Howitt, B. E., Sholl, L. M., Cin, P. D., Jia, Y., Yuan, L., MacConaill, L. E., Lindeman, N. I., Kuo, F. C., Garcia, E. P., Nucci, M. R., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4442 · Cited by 115 · see citing works
A “Twist box” Code of p53 Inactivation: Twist box:p53 Interaction Promotes p53 Degradation
Piccinin, S., Tonin, E., Sessa, S., Demontis, S., Rossi, S., Pecciarini, L., Zanatta, L., Pivetta, F., Grizzo, A., Sonego, M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.003 · Cited by 112 · see citing works
Zhang, Q. H., Ubago, J. M., Li, L., Guo, H., Liu, Y., Qiang, W., Kim, J. J., Kong, B., & Wei, J. (2014) · Cancer · doi:10.1002/cncr.28900 · Cited by 93 · see citing works
The Tyrosine Phosphatase PTPN14 Is a Negative Regulator of YAP Activity
Michaloglou, C., Lehmann, W., Martin, T., Delaunay, C., Hueber, A., Barys, L., Niu, H., Billy, É., Wartmann, M., Ito, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061916 · Cited by 90 · see citing works
Self-citationYang, C., Liau, J., Huang, W., Chang, Y., Chang, M., Lee, J., Tsai, J., Su, Y., Hung, C., & Jeng, Y. (2015) · Europe PMC (PubMed Central) · Cited by 88 · see citing works
Analysis ofMDM2Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies
Kato, S., Ross, J. S., Gay, L. M., Dayyani, F., Roszik, J., Subbiah, V., & Kurzrock, R. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00235 · Cited by 77 · see citing works
Choy, E., Hornicek, F. J., MacConaill, L. E., Harmon, D. C., Tariq, Z., Garraway, L. A., & Duan, Z. (2011) · Cancer · doi:10.1002/cncr.26617 · Cited by 70 · see citing works
Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma
Stolte, B., Iniguez, A. B., Dharia, N. V., Robichaud, A. L., Conway, A. S., Morgan, A. M., Alexe, G., Schauer, N. J., Liu, X., Bird, G. H., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20171066 · Cited by 67 · see citing works
Lenos, K., Grawenda, A. M., Lodder, K., Kuijjer, M. L., Teunisse, A. F. A. S., Repapi, E., Grochola, L. F., Bartel, F., Hogendoorn, P. C. W., Wuerl, P., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0215 · Cited by 65 · see citing works
The pharmacogenomics of osteosarcoma
Serra, M., & Hattinger, C. M. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.45 · Cited by 65 · see citing works
Urso, L., Calabrese, F., Favaretto, A. G., Conte, P., & Pasello, G. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.019 · Cited by 54 · see citing works
Targeting MDMX for Cancer Therapy: Rationale, Strategies, and Challenges
Yu, D.-H., Xu, Z., Mo, S., Li, Y., Cheng, X., & Qin, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01389 · Cited by 51 · see citing works
Targeted exome sequencing profiles genetic alterations in leiomyosarcoma
Agaram, N. P., Zhang, L., Loarer, F. L., Silk, T., Sung, Y., Scott, S. N., Kuk, D., Qin, L., Berger, M. F., Antonescu, C. R., et al. (2015) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22318 · Cited by 50 · see citing works
Leslie, P. L., Ke, H., & Zhang, Y. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.644435 · Cited by 50 · see citing works
Guled, M., Pazzaglia, L., Borze, I., Mosakhani, N., Novello, C., Benassi, M. S., & Knuutila, S. (2014) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22179 · Cited by 44 · see citing works
Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma
Ohnstad, H. O., Castro, R., Sun, J., Heintz, K., Vassilev, L. T., Bjerkehagen, B., Kresse, S. H., Meza‐Zepeda, L. A., & Myklebost, O. (2012) · Cancer · doi:10.1002/cncr.27837 · Cited by 42 · see citing works
Targeting Mdmx to treat breast cancers with wild-type p53
Haupt, S., Buckley, D., Pang, J.-M., Panimaya, J., Paul, P. J., Gamell, C., Takano, E. A., Lee, Y. Y., Hiddingh, S., Rogers, T.-M., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.173 · Cited by 42 · see citing works
Small molecules that target the ubiquitin system
Wu, H. Q., Baker, D. A., & Ovaa, H. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190535 · Cited by 41 · see citing works
Genomic gain of RRS1 promotes hepatocellular carcinoma through reducing the RPL11-MDM2-p53 signaling
Cao, P., Yang, A., Li, P., Xia, X., Han, Y., Zhou, G., Yang, F., Yang, F., Li, Y., Cui, Y., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf4304 · Cited by 40 · see citing works
Hyperprogression: A novel response pattern under immunotherapy
Han, X., Alu, A., Xiao, Y., Wei, Y., & Wei, X. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.167 · Cited by 39 · see citing works
The selected biomarker analysis in 5 types of uterine smooth muscle tumors
Zhang, Q., Kanis, M. J., Ubago, J. M., Liu, D., Scholtens, D. M., Strohl, A. E., Lurain, J. R., Shahabi, S., Kong, B., & Wei, J. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.12.005 · Cited by 38 · see citing works
Advances in sarcoma gene mutations and therapeutic targets
Gao, P., Seebacher, N. A., Hornicek, F. J., Guo, Z., & Duan, Z. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.001 · Cited by 36 · see citing works
Induction of p53-independent apoptosis by ectopic expression of HOXA5 in human liposarcomas
Lee, D. H., Forscher, C. A., Vizio, D. D., & Koeffler, H. P. (2015) · Scientific Reports · doi:10.1038/srep12580 · Cited by 33 · see citing works
Yang, J., Annala, M., Ji, P., Wang, G., Zheng, H., Codgell, D., Du, X., Fang, Z., Sun, B., Nykter, M., et al. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0076-2 · Cited by 33 · see citing works
Gambella, A., Bertero, L., Rondón‐Lagos, M., di Cantogno, L. V., Rangel, N., Pitino, C., Ricci, A. A., Mangherini, L., Castellano, I., & Cassoni, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021342 · Cited by 32 · see citing works
The PTEN Tumor Suppressor Gene in Soft Tissue Sarcoma
Sioletic, S., & Scambia, G. (2019) · Cancers · doi:10.3390/cancers11081169 · Cited by 32 · see citing works
Targeting the Molecular and Immunologic Features of Leiomyosarcoma
Cope, B. M., Traweek, R. S., Lazcano, R., Keung, E. Z.-Y., Lazar, A. J., Roland, C. L., & Nassif, E. F. (2023) · Cancers · doi:10.3390/cancers15072099 · Cited by 31 · see citing works
Dual Pten/Tp53 Suppression Promotes Sarcoma Progression by Activating Notch Signaling
Guijarro, M. V., Dahiya, S. M., Danielson, L. S., Segura, M. F., Vales-Lara, F. M., Menéndez, S., Popiolek, D. A., Mittal, K., Wei, J., Zavadil, J., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.02.035 · Cited by 29 · see citing works
Mouse models of sarcomas: critical tools in our understanding of the pathobiology
Post, S. M. (2012) · Clinical Sarcoma Research · doi:10.1186/2045-3329-2-20 · Cited by 26 · see citing works
Targeted Chemotherapy in Bone and Soft-Tissue Sarcoma
Harwood, J. L., Alexander, J. H., Mayerson, J. L., & Scharschmidt, T. J. (2015) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2015.06.011 · Cited by 25 · see citing works
Classification, Molecular Characterization, and the Significance ofPtenAlteration in Leiomyosarcoma
Grossmann, A. H., Layfield, L. J., & Randall, R. L. (2012) · Sarcoma · doi:10.1155/2012/380896 · Cited by 23 · see citing works
Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact
Hattinger, C. M., Patrizio, M. P., Luppi, S., & Serra, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134659 · Cited by 23 · see citing works
XI-006 induces potent p53-independent apoptosis in Ewing sarcoma
Pishas, K. I., Adwal, A., Neuhaus, S. J., Clayer, M., Farshid, G., Staudacher, A. H., & Callen, D. F. (2015) · Scientific Reports · doi:10.1038/srep11465 · Cited by 23 · see citing works
Cheng, J., Yan, Z., Jiang, K., Liu, C., Xu, D., Lyu, X., Hu, X., Zhang, S., Zhou, Y., Li, J., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01815 · Cited by 22 · see citing works
Lee, M.-Y., Marina, M. E., King, J. L., & Saavedra, H. I. (2014) · Cell Division · doi:10.1186/1747-1028-9-3 · Cited by 22 · see citing works
Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3
Yang, P., Chen, W., Li, X., Eilers, G., He, Q., Liu, L., Wu, Y., Wu, Y., Yu, W., Fletcher, J. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8999 · Cited by 21 · see citing works
Cai, X., & Yang, M. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-011-1124-8 · Cited by 21 · see citing works
Kitamoto, K., Miura, Y., Karnan, S., Ota, A., Konishi, H., Hosokawa, Y., & Sato, K. (2018) · Oncology Letters · doi:10.3892/ol.2018.8291 · Cited by 21 · see citing works
Optimal Clinical Management and the Molecular Biology of Angiosarcomas
Chen, T. W., Burns, J., Jones, R. L., & Huang, P. H. (2020) · Cancers · doi:10.3390/cancers12113321 · Cited by 21 · see citing works
Noncanonical roles of p53 in cancer stemness and their implications in sarcomas
Curylova, L., Ramos, H., Saraiva, L., & Skoda, J. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.037 · Cited by 21 · see citing works
Bozzi, F., Conca, E., Laurini, E., Posocco, P., Sardo, A. L., Jocollé, G., Sanfilippo, R. G., Gronchi, A., Perrone, F., Tamborini, E., et al. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.107 · Cited by 20 · see citing works
Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas
Chinyengetere, F., Sekula, D., Lu, Y., Giustini, A. J., Sanglikar, A., Kawakami, M., Ma, T., Burkett, S. S., Eisenberg, B. L., Wells, W. A., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1883-8 · Cited by 20 · see citing works
Gerarduzzi, C., de Polo, A., Liu, X.-S., El Kharbili, M., Little, J. B., & Yuan, Z.-M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.752303 · Cited by 19 · see citing works
Estimating TP53 Mutation Carrier Probability in Families with Li–Fraumeni Syndrome Using LFSPRO
Peng, G., Bojadzieva, J., Ballinger, M. L., Li, J., Blackford, A. L., Mai, P. L., Savage, S. A., Thomas, D. M., Strong, L. C., & Wang, W. (2017) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0695 · Cited by 19 · see citing works
Self-citationWang, L., Liu, Z., Jing, P., Shao, L., Chen, L., He, X., & Gong, W. (2013) · Tumor Biology · doi:10.1007/s13277-013-1227-8 · Cited by 18 · see citing works
Buchakjian, M. R., Merritt, N. M., Moose, D. L., Dupuy, A. J., Tanas, M. R., & Henry, M. D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183469 · Cited by 18 · see citing works
Touqan, N., Diggle, C. P., Verghese, E. T., Perry, S., Horgan, K. J., Merchant, W., Anwar, R., Markham, A. F., Carr, I., & Achuthan, R. (2013) · BMC Clinical Pathology · doi:10.1186/1472-6890-13-32 · Cited by 18 · see citing works
Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial Sarcoma
Landuzzi, L., Manara, M. C., Pazzaglia, L., Lollini, P., & Scotlandi, K. (2023) · Cancers · doi:10.3390/cancers15153887 · Cited by 17 · see citing works
Bandopadhayay, P., Jabbour, A. M., Riffkin, C. D., Salmanidis, M., Gordon, L., Popovski, D., Rigby, L., Ashley, D. M., Watkins, D. N., Thomas, D. M., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-585 · Cited by 17 · see citing works
Self-citationGenetic susceptibility to bone and soft tissue sarcomas: a field synopsis and meta-analysis
Benna, C., Simioni, A., Pasquali, S., Boni, D. D., Rajendran, S., Spiro, G., Colombo, C., Virgone, C., DuBois, S. G., Gronchi, A., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24719 · Cited by 16 · see citing works
A systematic review and meta-analysis of MDM2 polymorphisms in osteosarcoma susceptibility
for the Slovenian Osteosarcoma Study Group, Bilbao‐Aldaiturriaga, N., Ostolaza, Z. A., Granado-Tajada, I., Goričar, K., Dolžan, V., García‐Miguel, P., de Andoín, N. G., Martín‐Guerrero, I., & García‐Orad, Á. (2016) · Pediatric Research · doi:10.1038/pr.2016.120 · Cited by 15 · see citing works
Mirili, C., Paydaş, S., Güney, İ. B., Oğul, A., Gökçay, S., Büyükşimşek, M., Yetişir, A. E., Karaalioğlu, B., Tohumcuoğlu, M., & Şeydaoğlu, G. (2019) · Cancer Management and Research · doi:10.2147/cmar.s191199 · Cited by 15 · see citing works
Rasafar, N., Barzegar, A., & Aghdam, E. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-67510-8 · Cited by 15 · see citing works
Targeted therapy in sarcomas other than GIST tumors
Sborov, D. W., & Chen, J. L. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23802 · Cited by 14 · see citing works
Kandel, R. A., Yao, X., Dickson, B. C., Ghert, M. A., Popović, S., Purgina, B., Verma, S., & Werier, J. A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.005 · Cited by 14 · see citing works
The analysis of the pyroptosis-related genes and hub gene TP63 ceRNA axis in osteosarcoma
Han, J., Hu, Y., Ding, S., Liu, S., & Wang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.974916 · Cited by 12 · see citing works
Schubert, N. A., Lowery, C. D., Bergthold, G., Köster, J., Eleveld, T. F., Rodríguez, A. I. E., Jones, D., Vassal, G., Stancato, L. F., Pfister, S. M., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.01.027 · Cited by 12 · see citing works
Huang, X., Wu, F., Zhang, Z., & Shao, Z. (2019) · Bioscience Reports · doi:10.1042/bsr20181832 · Cited by 12 · see citing works
Chen, L., Li, J., Wu, X., & Zheng, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.687899 · Cited by 11 · see citing works
Biswas, S., Killick, E., Jochemsen, A. G., & Lunec, J. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.892924 · Cited by 11 · see citing works
Yang, J. (2014) · 癌症：英文版 · doi:10.5732/cjc.014.10209 · Cited by 10 · see citing works
Mauro, I. D., Mescam-Mancini, L., Chetaille, B., Lae, M. E., Pierron, G., Dadone‐Montaudié, B., Bazin, A., Bouvier, C., Michiels, J., & Pédeutour, F. (2020) · Neoplasia · doi:10.1016/j.neo.2020.05.003 · Cited by 10 · see citing works
Genetic heterogeneity and predictive biomarker for pulmonary sarcomatoid carcinomas
Qin, J., Chen, B., Li, C., Yan, J., & Lu, H. (2020) · Cancer Genetics · doi:10.1016/j.cancergen.2020.11.004 · Cited by 10 · see citing works
Mammalian models of bone sarcomas
Botter, S. M., Arlt, M., Born, W., & Fuchs, B. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-416721-6.00030-3 · Cited by 9 · see citing works
Novel Approaches to Treatment of Leiomyosarcomas
Collins, I. M., & Thomas, D. M. (2011) · Current Oncology Reports · doi:10.1007/s11912-011-0173-0 · Cited by 8 · see citing works
Self-citationZen, Y., & Sofue, K. (2019) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001349 · Cited by 8 · see citing works
Giner, F., Medina-Ceballos, E., López-Reig, R., Machado, I., López‐Guerrero, J. A., Navarro, S., Rubio-Martínez, L. A., Espino, M., Mayordomo‐Aranda, E., & Llombart-Bosch, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147615 · Cited by 7 · see citing works
Recurrent Osteosarcoma Presenting as an Isolated Bone Marrow Relapse
Liu, J. C., Cranmer, L. D., Larsen, B. T., Kuo, P. H., & Kopp, L. M. (2016) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000719 · Cited by 7 · see citing works
Biological characterization of soft tissue sarcomas.
Hayashi, T., Horiuchi, A., Sano, K., Kanai, Y., Yaegashi, N., Aburatani, H., & Konishi, I. (2015) · PubMed Central · doi:10.3978/j.issn.2305-5839.2015.12.33 · Cited by 7 · see citing works
Premalignant Conditions of Bone
Eckhoff, M. D., Wells, M. E., Padilla, O., Polfer, E. M., Castagno, C. J., Thabet, A. M., Elzamly, S., Wilson, H. L., & Rajani, R. (2022) · JAAOS Global Research and Reviews · doi:10.5435/jaaosglobal-d-22-00097 · Cited by 7 · see citing works
TP53-Deficient Angiosarcoma Expression Profiling in Rat Model
Smyczyńska, U., Strzemecki, D., Czarnecka, A. M., Fendler, W. M., Fiedorowicz, M., Wełniak-Kamińska, M., Guzowska, M., Synoradzki, K. J., Cheda, Ł., Rogulski, Z., et al. (2020) · Cancers · doi:10.3390/cancers12061525 · Cited by 5 · see citing works
Genetically Modified Mouse Models for Sarcoma Research: A Comprehensive Review
Remiszewski, P., Siedlecki, E., Wełniak-Kamińska, M., Mikuła, M., & Czarnecka, A. M. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01717-8 · Cited by 4 · see citing works
A 4-miRNA signature act as a novel prognostic biomarker in patients with Sarcoma
Chen, X., Cao, L., Xie, N., Xu, X., Liu, M., & Wang, K. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.07.46 · Cited by 3 · see citing works
A rare case of dedifferentiated liposarcoma of the sinonasal cavity: A case report
Miyazaki, M., Aoki, M., Oba, S., Sakata, T., Nakagawa, T., & Nabeshima, K. (2017) · Molecular and Clinical Oncology · doi:10.3892/mco.2017.1379 · Cited by 3 · see citing works
Long telomeres cooperate with p53, MDM 2, and p21 polymorphisms to raise pediatric solid tumor risk
Borbora, D., Dutta, H. K., Devi, K. R., Mahanta, J., Medhi, P., & Narain, K. (2019) · Pediatrics International · doi:10.1111/ped.13915 · Cited by 3 · see citing works
Kakazu, N., Yamane, H., Miyachi, M., Shiwaku, K., & Hosoi, H. (2014) · Cytogenetic and Genome Research · doi:10.1159/000357930 · Cited by 3 · see citing works
Multidisciplinary sarcoma care
Pollock, R. E., Payne, J. E., Rogers, A. D., Smith, S. J., Iwenofu, O. H., Valerio, I. L., Zomerlei, T. A., Howard, J. H., Dornbos, D., Galgano, M. A., et al. (2018) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2018.10.006 · Cited by 3 · see citing works
Bilbao‐Aldaiturriaga, N., Martín‐Guerrero, I., & García‐Orad, Á. (2014) · Tumor Biology · doi:10.1007/s13277-014-1882-4 · Cited by 2 · see citing works
Deng, W., Gao, S., Yan, L., Su, Q., & Chen, S. (2026) · Pharmaceuticals · doi:10.3390/ph19030476 · Cited by 1 · see citing works
Polymorphisms in the MDM2 gene and risk of malignant bone tumors: a meta-analysis
Tang, J., Shen, L., Song, S., An, Z., & Zhang, C. (2013) · Tumor Biology · doi:10.1007/s13277-013-1106-3 · Cited by 1 · see citing works
Meta-analisien erabilgarritasunaren analisi kritikoa
Bilbao‐Aldaiturriaga, N., Martín‐Guerrero, I., Gutiérrez-Camino, Á., López-López, E., & García‐Orad, Á. (2014) · EKAIA Euskal Herriko Unibertsitateko Zientzi eta Teknologi Aldizkaria · doi:10.1387/ekaia.11767 · Cited by 1 · see citing works
The MDM2 SNP309 G allele is not preferentially amplified in bone and soft tissue tumors
Mertens, F., Brosjö, O., von Steyern, F. V., Nord, K. H., & Mandahl, N. (2012) · Cancer Genetics · doi:10.1016/j.cancergen.2012.06.001 · Cited by 1 · see citing works
Molecular Pathology and Novel Therapy for Uterine Sarcomas
Hayashi, T., Sano, K., Ichimura, T., Kawano, M., Kanai, Y., Shiozawa, T., Yaegashi, N., & Konishi, I. (2017) · Comprehensive gynecology and obstetrics · doi:10.1007/978-981-10-2489-4_9 · Cited by 1 · see citing works
Devouassoux‐Shisheboran, M., & Croce, S. (2012) · ONCOLOGIE · doi:10.1007/s10269-012-2204-3 · Cited by 1 · see citing works
Touqan, N. (2014) · UPT. Syiah Kuala University Library (Syiah Kuala University)
Quantitative Assessment of the Association Between HDMX Polymorphism and Sarcoma
Xu, H., Zhou, P., Ti, Y., & Jia, F. (2014) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-0111-5
Molecular Approaches for Understanding of the Uterine Malignant Mesenchymal Tumours
Hayashi, T. (2015) · American Journal of Bioscience and Bioengineering · doi:10.11648/j.bio.20150305.14
LOODUS- JA TEHNOLOOGIATEADUSKOND MOLEKULAAR- JA RAKUBIOLOOGIA INSTITUUT
Ülikool, T. (2015)
Gene and proteomic profiling of osteosarcoma
Patiño‐García, A., & Lecanda, F. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-416721-6.00020-0
Candidate Molecules as Tumor Suppressor for Human Uterine Mesenchymal Tumor
Hayashi, T. (2013) · IOSR Journal of Pharmacy (IOSRPHR) · doi:10.9790/3013-0381031-37
- Authors
- Ito, M., Barys, L., O'Reilly, T., Young, S., Gorbatcheva, B., Monahan, J., Zumstein-Mecker, S., Choong, P. F., Dickinson, I., Crowe, P., Hemmings, C., Desai, J., Thomas, D. M., & Lisztwan, J.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- Authors' Affiliations: 1Novartis Institutes for Biomedical Research, Oncology Research, Basel, Switzerland; 2Peter MacCallum Cancer Centre, Melbourne, Australia; 3Novartis Institutes for Biomedical Research, Oncology Translational Medicine, Cambridge, Massachusetts; 4Wesley Research Institute, Brisbane, Australia; 5Prince of Wales Hospital, Sydney, Australia; and 6Canberra Hospital, Canberra, Australia
- Venue
- Clinical Cancer Research
- Published
- 2011-02-01
- Volume
- 17
- Issue
- 3
- Pages
- 416-426
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2056955003
- Cited by
- 115
- References
- 57
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 2 · 2023: 5 · 2022: 2 · 2021: 5 · 2020: 10 · 2019: 7 · 2018: 7 · 2017: 7 · 2016: 9 · 2015: 17 · 2014: 16 · 2013: 10 · 2012: 10
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- ANU Open Research (Australian National University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- p53 pathway, sarcomagenesis, soft tissue sarcoma, MDM2 amplification, TP53 mutation, CDKN2A, MDM2 SNP309, liposarcoma, lipoma, leiomyosarcoma, osteosarcoma, sarcoma subtypes, MDM2 inhibitors, tumor suppressor inactivation
- MeSH terms
- Bone Neoplasms, Chromosome Mapping, Gene Amplification, Humans, Mutation, Sarcoma, Soft Tissue Neoplasms, Biomarkers, Tumor, Genes, p53, Gene Dosage, Polymorphism, Single Nucleotide, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
